4KFN
Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors
4KFN の概要
| エントリーDOI | 10.2210/pdb4kfn/pdb |
| 関連するPDBエントリー | 4JR5 4KFO |
| 分子名称 | Nicotinamide phosphoribosyltransferase, N-[4-(piperidin-1-ylsulfonyl)benzyl]-1H-pyrrolo[3,2-c]pyridine-2-carboxamide, PHOSPHATE ION, ... (5 entities in total) |
| 機能のキーワード | transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| 由来する生物種 | Homo sapiens (human) |
| 細胞内の位置 | Cytoplasm (By similarity): P43490 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 115872.21 |
| 構造登録者 | Zheng, X.,Bauer, P.,Baumeister, T.,Buckmelter, A.J.,Caligiuri, M.,Clodfelter, K.H.,Han, B.,Ho, Y.,Kley, N.,Lin, J.,Reynolds, D.J.,Sharma, G.,Smith, C.C.,Wang, Z.,Dragovich, P.S.,Gunzner-Toste, J.,Liederer, B.M.,Ly, J.,O'Brien, T.,Oh, A.,Wang, L.,Wang, W.,Xiao, Y.,Zak, M.,Zhao, G.,Yuen, P.,Bair, K.W. (登録日: 2013-04-27, 公開日: 2013-05-08, 最終更新日: 2024-02-28) |
| 主引用文献 | Zheng, X.,Bauer, P.,Baumeister, T.,Buckmelter, A.J.,Caligiuri, M.,Clodfelter, K.H.,Han, B.,Ho, Y.C.,Kley, N.,Lin, J.,Reynolds, D.J.,Sharma, G.,Smith, C.C.,Wang, Z.,Dragovich, P.S.,Oh, A.,Wang, W.,Zak, M.,Gunzner-Toste, J.,Zhao, G.,Yuen, P.W.,Bair, K.W. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (nampt) inhibitors. J.Med.Chem., 56:4921-4937, 2013 Cited by PubMed Abstract: Nicotinamide phosphoribosyltransferase (Nampt) is a promising anticancer target. Virtual screening identified a thiourea analogue, compound 5, as a novel highly potent Nampt inhibitor. Guided by the cocrystal structure of 5, SAR exploration revealed that the corresponding urea compound 7 exhibited similar potency with an improved solubility profile. These studies also indicated that a 3-pyridyl group was the preferred substituent at one inhibitor terminus and also identified a urea moiety as the optimal linker to the remainder of the inhibitor structure. Further SAR optimization of the other inhibitor terminus ultimately yielded compound 50 as a urea-containing Nampt inhibitor which exhibited excellent biochemical and cellular potency (enzyme IC50 = 0.007 μM; A2780 IC50 = 0.032 μM). Compound 50 also showed excellent in vivo antitumor efficacy when dosed orally in an A2780 ovarian tumor xenograft model (TGI of 97% was observed on day 17). PubMed: 23617784DOI: 10.1021/jm400186h 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.6 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






